Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Morphine
Drug ID BADD_D01498
Description Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805.[A176035] It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse.[A176050] Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941.[L12114]
Indications and Usage For the relief and treatment of severe pain.
Marketing Status Prescription; Discontinued
ATC Code N02AA01
DrugBank ID DB00295
KEGG ID D08233
MeSH ID D009020
PubChem ID 5288826
TTD Drug ID D0WE3O
NDC Product Code 42799-217
Synonyms Morphine | Morphia | Morphine Chloride | Chloride, Morphine | Morphine Sulfate | Sulfate, Morphine | SDZ 202-250 | SDZ 202 250 | SDZ 202250 | SDZ202-250 | SDZ202 250 | SDZ202250 | Morphine Sulfate (2:1), Pentahydrate | MS Contin | Contin, MS | Oramorph SR | Duramorph | Morphine Sulfate (2:1), Anhydrous
Chemical Information
Molecular Formula C17H19NO3
CAS Registry Number 57-27-2
SMILES CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cardiac arrhythmiasMu-type opioid receptorP35372T477688383026; 1528399; 1654493; 8490741; 1279757; 7521466
Cardiac arrhythmiasMu-type opioid receptorP35372T4776825806604
HyperpathiaMu-type opioid receptorP35372T4776825806604
HyperpathiaMitogen-activated protein kinase 8P45983T4009725806604
HyperpathiaProtein kinase C alpha typeP17252T1280825806604
HyperpathiaMu-type opioid receptorP35372T477688383026; 1528399; 1654493; 8490741; 1279757; 7521466
HyperpathiaTranscription factor JunP05412T6908525806604
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gamma-glutamyltransferase increased13.03.01.011--
Gastric atony07.02.02.009--Not Available
Gastric haemorrhage24.07.02.007; 07.12.01.001--
Gastrooesophageal reflux disease07.02.02.003--
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage07.12.02.001; 24.07.02.009--Not Available
Gastrointestinal pain07.01.05.005--
Generalised oedema14.05.06.007; 08.01.07.004--
Generalised tonic-clonic seizure17.12.01.002--Not Available
Granuloma23.03.15.001; 08.01.05.0010.002343%Not Available
Gynaecomastia21.05.04.003; 05.05.02.003--
Haematemesis24.07.02.011; 07.12.02.002--Not Available
Haematocrit decreased13.01.05.001--Not Available
Haematuria24.07.01.047; 20.02.01.006--
Haemoglobin decreased13.01.05.003--Not Available
Haemoptysis02.01.02.006; 24.07.01.006; 22.02.03.004--Not Available
Haemorrhage intracranial24.07.04.003; 17.08.01.008--
Hallucination19.10.02.0020.031162%
Hallucination, auditory19.10.02.003--Not Available
Hallucination, visual19.10.02.0040.004686%Not Available
Hallucinations, mixed19.10.02.0070.000937%Not Available
Hangover08.01.09.0180.000469%Not Available
Head injury12.01.09.003--Not Available
Headache17.14.01.001--
Heart rate decreased13.14.04.0010.001874%Not Available
Heart rate increased13.14.04.002--Not Available
Heart rate irregular13.14.04.003--Not Available
Heat stroke24.06.02.009; 12.05.01.0010.000937%Not Available
Hepatic necrosis09.01.07.0020.000183%
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 21 Pages